Radiosensitization of metformin in pancreatic cancer cells via abrogating the G2 checkpoint and inhibiting DNA damage repair

Cancer Letters

Volumn 369, Issue 1, 2015, Pages 192-201

  Wang, Zheng ^a,b   Lai, Song Tao ^a,b   Ma, Ning Yi ^a,b   Deng, Yun ^a   Liu, Yong ^a   Wei, Dong Ping ^a   Zhao, Jian Dong ^a,b   Jiang, Guo Liang ^a,b,c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c Shanghai Proton and Heavy Ion Center   (China)

Author keywords

Metformin; MTOR; Pancreatic cancer; Rad51; Radiosensitizer; Wee1

Indexed keywords

53BP1 PROTEIN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE 1; HISTONE H2AX; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; RAD51 PROTEIN; RADIOSENSITIZING AGENT; REGULATOR PROTEIN; S6 KINASE; UNCLASSIFIED DRUG; WEE1 KINASE; CDK1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; NUCLEAR PROTEIN; PROTEIN TYROSINE KINASE; RAD51 PROTEIN, HUMAN; WEE1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RADIOSENSITIVITY; TRANSLATION REGULATION; ANTAGONISTS AND INHIBITORS; CHEMORADIOTHERAPY; DNA DAMAGE; DRUG EFFECTS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHEMORADIOTHERAPY; CYCLIN-DEPENDENT KINASES; DNA DAMAGE; DNA REPAIR; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; METFORMIN; MITOSIS; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-TYROSINE KINASES; RAD51 RECOMBINASE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 84943457185     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.08.015     Document Type: Article

References (50)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin 2011, 61:69-90.
2. Simeone D.M. Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin. Cancer Res 2008, 14:5646-5648.
3. Goodman K.A., Hajj C. Role of radiation therapy in the management of pancreatic cancer. J. Surg. Oncol 2013, 107:86-96.
4. Huguet F., Mukherjee S., Javle M. Locally advanced pancreatic cancer: the role of definitive chemoradiotherapy. Clin. Oncol 2014, 26:560-568.
5. Bailey C.J., Turner R.C. Metformin. N. Engl. J. Med 1996, 334:574-579.
6. Zhang P., Li H., Tan X., Chen L., Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 2013, 37:207-218.
7. Wang Z., Lai S.T., Xie L., Zhao J.D., Ma N.Y., Zhu J., et al. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res. Clin. Pract 2014, 106:19-26.
8. Sadeghi N., Abbruzzese J.L., Yeung S.C., Hassan M., Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin. Cancer Res 2012, 18:2905-2912.
9. Hwang A.L., Haynes K., Hwang W.T., Yang Y.X. Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas 2013, 42:1054-1059.
10. Bao B., Wang Z., Ali S., Ahmad A., Azmi A.S., Sarkar S.H., et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev. Res 2012, 5:355-364.
11. Karnevi E., Said K., Andersson R., Rosendahl A.H. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer 2013, 13:235.
12. Kisfalvi K., Moro A., Sinnett-Smith J., Eibl G., Rozengurt E. Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas 2013, 42:781-785.
13. Song C.W., Lee H., Dings R.P., Williams B., Powers J., Santos T.D., et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci. Rep 2012, 2:362.
14. Storozhuk Y., Hopmans S.N., Sanli T., Barron C., Tsiani E., Cutz J.C., et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br. J. Cancer 2013, 108:2021-2032.
15. Kim E.H., Kim M.S., Cho C.K., Jung W.G., Jeong Y.K., Jeong J.H. Low and high linear energy transfer radiation sensitization of HCC cells by metformin. J. Radiat. Res. (Tokyo) 2014, 55:432-442.
16. Zhang T., Zhang L., Zhang T., Fan J., Wu K., Guan Z., et al. Metformin sensitizes prostate cancer cells to radiation through EGFR/p-DNA-PKCS in vitro and in vivo. Radiat. Res 2014, 181:641-649.
17. Fasih A., Elbaz H.A., Huttemann M., Konski A.A., Zielske S.P. Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway. Radiat. Res 2014, 182:50-59.
18. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
19. Pawlik T.M., Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys 2004, 59:928-942.
20. Krajewska M., Heijink A.M., Bisselink Y.J., Seinstra R.I., Sillje H.H., de Vries E.G., et al. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene 2013, 32:3001-3008.
21. Pollak M. Metformin and pancreatic cancer: a clue requiring investigation. Clin. Cancer Res 2012, 18:2723-2725.
22. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
23. Sikka A., Kaur M., Agarwal C., Deep G., Agarwal R. Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle 2012, 11:1374-1382.
24. Luo Q., Hu D., Hu S., Yan M., Sun Z., Chen F. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC Cancer 2012, 12:517.
25. Habibollahi P., van den Berg N.S., Kuruppu D., Loda M., Mahmood U. Metformin - an adjunct antineoplastic therapy - divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging. J. Nucl. Med 2013, 54:252-258.
26. Dixon H., Norbury C.J. Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle 2002, 1:362-368.
27. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther 2004, 3:513-519.
28. Masaki T., Shiratori Y., Rengifo W., Igarashi K., Yamagata M., Kurokohchi K., et al. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 2003, 37:534-543.
29. Mir S.E., De Witt Hamer P.C., Krawczyk P.M., Balaj L., Claes A., Niers J.M., et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 2010, 18:244-257.
30. PosthumaDeBoer J., Wurdinger T., Graat H.C., van Beusechem V.W., Helder M.N., van Royen B.J., et al. WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer 2011, 11:156.
31. Magnussen G.I., Hellesylt E., Nesland J.M., Trope C.G., Florenes V.A., Holm R. High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients. BMC Cancer 2013, 13:288.
32. Magnussen G.I., Holm R., Emilsen E., Rosnes A.K., Slipicevic A., Florenes V.A. High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS ONE 2012, 7:e38254.
33. De Witt Hamer P.C., Mir S.E., Noske D., Van Noorden C.J., Wurdinger T. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin. Cancer Res 2011, 17:4200-4207.
34. Vriend L.E., De Witt Hamer P.C., Van Noorden C.J., Wurdinger T. WEE1 inhibition and genomic instability in cancer. Biochim. Biophys. Acta 1836, 2013:227-235.
35. Do K., Doroshow J.H., Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle 2013, 12:3159-3164.
36. Morgan M.A., Parsels L.A., Maybaum J., Lawrence T.S. Improving the efficacy of chemoradiation with targeted agents. Cancer Discov 2014, 4:280-291.
37. Bridges K.A., Hirai H., Buser C.A., Brooks C., Liu H., Buchholz T.A., et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin. Cancer Res 2011, 17:5638-5648.
38. Caretti V., Hiddingh L., Lagerweij T., Schellen P., Koken P.W., Hulleman E., et al. WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas. Mol. Cancer Ther 2013, 12:141-150.
39. Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001, 439:798-802.
40. Sipos B., Moser S., Kalthoff H., Torok V., Lohr M., Kloppel G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 2003, 442:444-452.
41. Xiao Z., Xue J., Gu W.Z., Bui M., Li G., Tao Z.F., et al. Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors. Biomarkers 2008, 13:579-596.
42. Shrivastav M., De Haro L.P., Nickoloff J.A. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008, 18:134-147.
43. Jeggo P.A., Geuting V., Lobrich M. The role of homologous recombination in radiation-induced double-strand break repair. Radiother. Oncol 2011, 101:7-12.
44. Collis S.J., Tighe A., Scott S.D., Roberts S.A., Hendry J.H., Margison G.P. Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 2001, 29:1534-1538.
45. Sak A., Stueben G., Groneberg M., Bocker W., Stuschke M. Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines. Br. J. Cancer 2005, 92:1089-1097.
46. Liu Q., Jiang H., Liu Z., Wang Y., Zhao M., Hao C., et al. Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51. PLoS ONE 2011, 6:e23427.
47. Choudhury A., Zhao H., Jalali F., Al Rashid S., Ran J., Supiot S., et al. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol. Cancer Ther 2009, 8:203-213.
48. Adimoolam S., Sirisawad M., Chen J., Thiemann P., Ford J.M., Buggy J.J. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:19482-19487.
49. Gasparini P., Lovat F., Fassan M., Casadei L., Cascione L., Jacob N.K., et al. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:4536-4541.
50. Havelek R., Cmielova J., Kralovec K., Bruckova L., Bilkova Z., Fousova I., et al. Specific inhibition of Wee1 kinase and Rad51 recombinase: a strategy to enhance the sensitivity of leukemic T-cells to ionizing radiation-induced DNA double-strand breaks. Biochem. Biophys. Res. Commun 2014, 453:569-575.